The concept of precision medicine has always been to tailor therapies to the individual but historically, much of the approach has to been to tailor therapy to pathogens or tumors. As we expand beyond the infectious disease and oncology spaces, the shift from “pathogen genetics” to human genetics can become a reality.
Nowhere in healthcare is the economic and human burden as high as it is in rheumatic and neurodegenerative disease. This economic and human burden is such that there is an urgent need for true precision medicine approaches to support the easing of the economic pressures and drive improved patient outcomes.
This workshop will explore the unique challenges in executing a precision medicine strategy in neurology and bring together multiple stakeholders to discuss the advancement of care in the field.